Search academic texts

Information × Registration Number 0215U003240, 0113U002146 , R & D reports Title To develop technology of reception melanoma-specific transferfactor polypeptides and to prove expediency of their application for skin melanoma patients popup.stage_title Head Filchakov F.V., Registration Date 22-01-2015 Organization National Cancer Institute popup.description2 Object of research: immunocompetent cells, dialisable extract of human leukocytes. The purpose - To prove experimentally the new approach to treatment of skin melanoma patients by carrying over tumor-specific immunoreactivity by transferfactor polypeptides (TFP). Methods of research - immunological, flow cytometry, a method of cell culture, statistical. The equipment: centrifuges ОPN-3, ОPN-8, Т 23; a microscope; flowing cytometer FACScan; the automatic sampleres; termostates; the СО2-incubator. Clinical and immunological study of 40 patients with generalized skin melanoma was carried out. Patients in the control group (20 patients) received standard chemotherapy (CT), dacarbazine (2 courses); patients from the main group (20 patients) in addition to this treatment prescribed drug of transfer factor (TF, dialysate leukocytes from healthy donors "Immodin", generally 4 doses). It was found that patients with generalized skin melanoma are characterized by dysfunction of the immune system, exacerbated during CT. Clinical and laboratory criteria for the diagnosis of these disorders are the development of lymphocytopenia with signs of T-cell immunodeficiency (by reducing the number of cytotoxic T-lymphocytes), a significant increase in the proportion of regulatory T cells and activated lymphocytes in the circulation, as well as inhibition of mitogen-induced proliferation and cytotoxic activity lymphocytes in vitro. Under these conditions, drug of TF, acting exclusively on the T-cell mechanisms of immune homeostasis and prevents the development of deep disorders in the immune system of patients during CT. An important result of the combined chemoimmunotherapy is to restore the number of lymphocytes (including subpopulations of cytotoxic T-lymphocytes), a decrease in the number of circulating regulatory T cells and the preservation of the functional activity of the T-cell population, which may affect the effectiveness of the primary treatment of these patients. GENERALIZED SKIN MELANOMA, TRANSFER FACTOR POLYPEPTIDES , CHEMOIMMUNOTHERAPY, LYMPHOCYTES, DYSFUNCTION OF IMMUNE SYSTEM Product Description popup.authors Кукушкіна С.М. Льон Г.Д. Шуміліна К.С. popup.nrat_date 2020-04-02 Close